 |
Related Articles |
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Dermatology. 2008;216(3):247-9
Authors: Lübbe J, Masouyé I, Dietrich PY
Erlotinib is a small molecule tyrosine kinase inhibitor that is used as an anticancer agent. Most patients develop a pustular facial dermatitis within the first week of treatment. Pyogenic granulomas of the nail folds are another typical adverse event occurring in about 10-15% of cases. We report on a patient who developed a generalized dermatitis characterized by neutrophilic spongiosis. Neutrophilic inflammation has been observed in several drugs that interfere with EGFR signaling, suggesting a class effect. The present case may be yet another manifestation of this particular reaction pattern.
PMID: 18182820 [PubMed - indexed for MEDLINE]
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.